Dr. Michael P. Digiovanna, MD

Dr. Digiovanna practices at Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut.

Dr. Digiovanna's NPI, 1023006947, was assigned on October 13, 2005. Dr. Digiovanna graduated from Yale School of Medicine in 1990. Dr. Digiovanna holds Connecticut license 033231.

Dr. Digiovanna's primary practice is Yale New Haven Psychiatric Hospital (York St), at 20 York Street, New Haven, CT 06510. The practice phone is (203) 688-5900.

Dr. Digiovanna's primary practice is Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut. Dr. Digiovanna is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Digiovanna to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Digiovanna practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Digiovanna's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Digiovanna is licensed in Connecticut.

CMS data shows 158 Medicare services from Dr. Digiovanna across 4 procedure codes in 2024, for 98 Medicare patients. Medicare paid $12,780 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 98 Medicare patients who saw Dr. Digiovanna in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have cancer, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Digiovanna's median patient age at 72, with 91% women.

In 2024, Dr. Digiovanna wrote 139 Medicare Part D claims for 45 patients. 92% of them were for generic drugs. CMS names the drug for 76 of them, across 2 drugs with 11 or more claims each, at $1,721 in total drug cost. In 2023, CMS named 62 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Digiovanna for performance year 2024, reported as part of a group. Dr. Digiovanna accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Digiovanna as offering telehealth.

Dmand AI links 30 papers to Dr. Digiovanna, published from 2008 to 2025. 2017 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Receptor, ErbB-2 and Trastuzumab. Dr. Digiovanna has published most often in Breast Cancer Res Treat. Dr. Digiovanna's most frequent co-authors are Tara B. Sanft, MD, Lajos Pusztai, MD and Maysa M. Abu-Khalaf, MD.

Dmand AI links Dr. Digiovanna to 5 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Brain Neoplasms. Exact Sciences Corporation sponsors the most, 2.

CMS Open Payments shows 62 general payments to Dr. Digiovanna from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 63% of the total. Merck Sharp & Dohme Corporation paid the most, $7,179. It also lists 3 research payments totaling $3,803 from 2020 to 2024.

Dr. Digiovanna graduated from Yale School of Medicine in 1990.